Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

CSL (ASX:CSL) has ramped up its research and development efforts via a US$355 million ($515m)-plus drug development collab with private Swiss group Alentis Therapeutics.

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.couriermail.com.au)